Contract 36E79724D0002
Biogen U.S. Corporation · Department Of Veterans Affairs · January 31, 2025
Biogen U.S. Corporation was awarded a federal contract by Department Of Veterans Affairs on January 31, 2025 for an undisclosed amount of work in pharmaceutical preparation manufacturing. It was awarded under full and open competition. The contract has been modified 1 time since the base award It uses firm fixed-price contract pricing. The most recent modification was on November 25, 2025. If all options are exercised, the contract could reach $11.39 million.
Contract details
- PIID
- 36E79724D0002
- Award type
- Indefinite Delivery / Requirements
- Pricing
- Firm Fixed Price
- Set-aside
- No Set Aside Used.
- Competition
- Full And Open Competition
- NAICS
- 325412 · Pharmaceutical Preparation Manufacturing
- Product / service
- Drugs And Biologicals
- First action
- January 31, 2025
- Latest action
- November 25, 2025
Description
BILATERAL MODIFICATION IS ISSUED TO NOTIFY BIOGEN U.S. CORPORATION, THAT THE GOVERNMENT WILL NOT EXERCISE THE 2ND OPTION YEAR FOR RANIBIZUMAB (BYOOVIZ) VIALS. THE CONTRACT WILL EXPIRE ON 12/22/2025 AT THE END OF THE 1ST OPTION YEAR.
Modification timeline
-
November 25, 2025Mod P00008 · Other Administrative Action$0
-
January 31, 2025Mod P00007$0
Similar contracts
| Recipient | Agency | Date | Obligated |
|---|---|---|---|
| Petnet Solutions, Inc. | Department Of Veterans Affairs | April 1, 2026 | $387.4K |
| Eli Lilly And Company | Department Of Veterans Affairs | April 1, 2026 | $0 |
| Exelan Pharmaceuticals Inc | Department Of Veterans Affairs | April 1, 2026 | $0 |
| Cardinal Health 414, Llc | Department Of Veterans Affairs | April 1, 2026 | $122.9K |
| Guardian Pharmacy Of Indianapolis Nuclear, Llc | Department Of Veterans Affairs | April 1, 2026 | $0 |
| Jubilant Draximage Inc | Department Of Veterans Affairs | April 1, 2026 | $0 |
Top contractors in NAICS 325412
Lifetime obligated dollars across all federal contracts in this NAICS code.
| # | Contractor | Contracts | Obligated |
|---|---|---|---|
| 1 | Mckesson Corporation | 1,187 | $4.96B |
| 2 | Merck Sharp & Dohme Llc | 26 | $894.71M |
| 3 | Sanofi Vaccines Us Inc. | 57 | $702.38M |
| 4 | Pfizer Inc | 169 | $541.15M |
| 5 | Glaxosmithkline, Llc | 14 | $505.04M |
| 6 | Phlow Corp. | 1 | $105.27M |
| 7 | Exelan Pharmaceuticals Inc | 76 | $104.30M |
| 8 | Seqirus USA Inc | 47 | $59.15M |
| 9 | Emergent Biosolutions Canada Inc | 2 | $53.73M |
| 10 | Mckesson Specialty Distribution Llc | 1 | $51.05M |
Track this on BesaGov
Get a free weekly email when this changes — new awards, new sub-awards, new opportunities. No login required.
Continue learning
Keep researching
Frequently asked questions
What is contract 36E79724D0002?
Contract 36E79724D0002 is a federal contract awarded to Biogen U.S. Corporation by Department Of Veterans Affairs on January 31, 2025 for an undisclosed amount of work classified under PHARMACEUTICAL PREPARATION MANUFACTURING. It has been modified 1 time since the base award.
Who won contract 36E79724D0002?
Biogen U.S. Corporation won contract 36E79724D0002 from Department Of Veterans Affairs.
How much is contract 36E79724D0002 worth?
Contract 36E79724D0002 has obligated $0 to date but carries a potential ceiling of $11.39 million if fully funded and all options are exercised.